Press release
Primary Immune Deficiency Diseases Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results
Download the sample report @ https://www.pharmaproff.com/request-sample/1051
Primary immune deficiency diseases can occur due to B-cell deficiencies, T-cell deficiencies, defective phagocytes, combination of B- and T-cell deficiencies, and complement deficiencies.
Get the detailed analysis @ https://www.pharmaproff.com/report/primary-immune-deficiency-diseases-therapeutics-pipeline-analysis
The only risk factor associated with this disease is family history. GigaGen Inc. is in the process of developing recombinant intravenous immunoglobulin (rIVIG) for the treatment of primary immune deficiency diseases. X4 Pharmaceuticals Inc. is in the process of developing X4P-001-RD as a CXCR4 receptor antagonist for the treatment this disease. Orchard Therapeutics Ltd. is also engaged in the pipeline for this disorder.
Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1051
• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Immune Deficiency Diseases Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results here
News-ID: 1695655 • Views: 443
More Releases from Pharma Proff
Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates.
IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to…
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates.
Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete…
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome.
Download the sample report at: https://www.pharmaproff.com/request-sample/1189
Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in…
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances…
More Releases for Primary
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
Global Primary Sclerosing Cholangitis Market
The Primary Sclerosing Cholangitis report offers insights into vital aspects like growth,CAGR value, market share and revenue analysis. It evaluates the growth opportunities, threats, market drivers and risks involved. understand the market competition by analyzing the top vendors, with their market profile, revenue, profits, import-export details, and market share. it states the pricing structure, import-export details, supply chain analysis, SWOT analysis to facilitate the key decision-making process. This report helps…
Primary Lithium Battery (Primary Lithium Batteries) Industry Analysis by 2025: …
In its recently published report, QY Research has provided unique insights about global Primary Lithium Battery (Primary Lithium Batteries) market for the given period. One of the main objectives of this report is to categorize the various dynamics of the market and to offer latest updates such as mergers and acquisitions, various technological developments, new entrants in the market, which make an impact on different segments of the global Primary…
Primary Cells And Primary Batteries Market Analysis by Production Capacity, Dyna …
This report helps to analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Primary Cells And Primary Batteries market.
Description
The Global Primary Cells And Primary Batteries Market report offers a comprehensive evaluation of the Global Primary Cells And Primary Batteries industry. This report evaluates the Global market for " Global Primary Cells And Primary Batteries".
The Global Primary Cells…
Primary Immunodeficiency Diseases Market: Key Insights
With only a handful of companies enjoying the major share of the revenue pie, the global primary immunodeficiency diseases (PIDD) market exhibits a consolidated vendor landscape. As per Transparency Market Research (TMR), CSL Behring LLC and Grifols S.A. emerged dominant in the market with a share of 60.5% in 2014. Baxter International, Inc. and Octapharma AG are other prominent enterprises operating in the global PIDD market.
These companies have been…
Global Primary Biliary Cholangitis Treatment Market is Driven by Rise in Inciden …
Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a rare chronic liver disease, primarily characterized by destruction of the bile ducts which transport bile acid out of the liver. Although the primary cause of the disease has not yet been elucidated, research across the world has attributed it to be autoimmune in nature. The progress of this disease results in the harmful accumulation of bile acid, which causes…
